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bstract
A simple and rapid stability-indicating LC-analytical method was developed for the simultaneous determination of flucloxacillin
fluc) and amoxicillin (amox) in bulk and pharmaceutical dosage form. A chromatographic separation of the two drugs was achieved
ith a Thermosil C18 (4.6 mm ×  250 mm, 5 m) analytical column using potassium dihydrogen phosphate buffer (adjusted to pH 3
y ortho phosphoric acid):methanol (70:30%, v/v) in isocratic mode at a flow rate of 1 mL/min and column at ambient temperature.
he detection was monitored at 225 nm using a PDA detector. The stressed samples were analyzed for the degradation study in
cid, base, peroxide, thermal, photolytic and validated as per ICH guideline. This proposed method was found to be specific and
tability-indicating as no interfering peaks of degradation compounds and excipients were noticed. The described method shows
xcellent linearity over a range of 20–100 g/mL for both drugs. The correlation coefficient for fluc and amox was 0.9992 and
.9993, respectively. The mean recovery value for fluc and amox was 99.9% and 99.7%, respectively. The limit of detection for
uc and amox was 0.018 and 0.009 g/mL and the limit of quantification was 0.06 and 0.03 g/mL, respectively. The retention
ime was observed at 2.582 and 3.407 min for amox and fluc, respectively. The robustness study and percentage of assay of the
ormulation were found within limit as per ICH guidelines. The proposed method was suitable for quantitative determination and
t can be applied in quality control department in industries, approved testing laboratories, bio-pharmaceutics and bio-equivalence
nd clinical pharmacokinetic studies.
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1.  Introduction
Flucloxacillin sodium [1] chemically is (2S, 5R,
6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxaz-
ole-4-yl]carbonyl}amino)-3, 3-dimethyl-7-oxo-4-thia-. This is an open access article under the CC BY-NC-ND license
1-azabicyclo [3.2.0] heptane-2-carboxylicacid and
amoxicillin trihydrate [2] (2S, 5R, 6R)-6-[[(2R)-
2-amino-2-(4-hydroxy phenyl)acetyl]amino]-3,
3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]
ibah Un
ther pipette 0.6 mL of amox and fluc in the above stock
solution into a 10 mL volumetric flask and dilute up to
the mark with mobile phase.
Table 1
Optimized chromatographic parameters.
Equipment High performance liquid chromatography
equipped with Auto Sampler and DAD or UV
detector
Column Symmetry C18 (4.6 mm × 150 mm, 5 m, make:
Thermosil) or equivalent
Flow rate 1.0 mL/min168 S.N. Konari, J.T. Jacob / Journal of Ta
heptane-2-carboxylicacid tri hydrate. Flumox is a
combination of two bactericidal penicillins: amoxy-
cillin (broad-spectrum penicillin) and flucloxacillin
(penicillin-resistant penicillin), to produce a wider
spectrum of activity. Flucloxacillin exerts a bactericidal
action on penicillinase-producing microorganisms
including most staphylococci. This combination
exhibits bactericidal activity against a wide range
of gram-positive and gram-negative microorganisms
including penicillinase and non-penicillinase-producing
Staphylococci, Streptococcus  pyogenes, pneumoniae,
and faecalis, Corynebacterium  diphtheriae, Clostridia
spp., Bacillus  anthracis; Haemophilus  inﬂuenzae,
Moraxella (Branhamella) catarrhalis, Neisseria  gon-
orrheae and meningitidis, Escherichia  coli, Proteus
mirabilis, Salmonella, Bordetella  pertussis  and Bac-
teroides melaninogenicus. Literature review reveals
that few spectrophotometric and potentiometric meth-
ods have been reported for analysis of flucloxacillin
alone [3–5] or method development in combination
with ampicillin in LC–MS [6] and in LC [7] or with
amoxicillin by liquid chromatography without forced
degradation study [8,9] for pharmaceutical injection
[10] and ion-pairs along with gradient elution HPLC
method [11]. Although two LC simultaneous methods
for pharmaceutical dosage and one for injections were
reported in the literature review, existing methods were
not subjected to forced degradation study. Moreover
reported methods were not much cost-effective in
terms of solvent consumption and total run time of the
analysis, so we decided to perform rapid, selective and
precise stability-indicating isocratic RP-HPLC assay
method for simultaneous determination of flucloxacillin
and amoxicillin in solid dosage form which was not
developed so far.
2.  Experimental
2.1.  Chemicals  and  reagents
Flucloxacillin standards were obtained from Surya
Pharmaceutical Limited and amoxicillin trihydrate
from ABL-Life Care Limited. Methanol (HPLC-grade)
was obtained from Merck Fine Chemicals (Mumbai,
India). Sodium hydroxide (NaOH), hydrochloric acid
(HCl) and hydrogen peroxide (H2O2) were from SD
Fine Chemicals, Finar Chemicals and Alpha Pharma
Limited, respectively. The 0.45-m pump nylon filter
was obtained from advanced micro devices (Ambala
Cantt, India). The flucamox (Sedico Pharmaceuticals)
and flumox (Eipico) capsules of the combination ofiversity for Science 9 (2015) 167–176
flucloxacillin and amoxicillin were purchased commer-
cially. Double-distilled water was used throughout the
experiment. Other chemicals used were of analytical or
HPLC-grade.
2.2.  HPLC  instrumental  condition
Instrument used in the study was Shimadzu-LC
equipped with Auto Sampler, DAD or UV detector
and Empower 2 software. A chromatographic separa-
tion of the two drugs was achieved with a Thermosil
C18 (4.6 mm ×  250 mm, 5 m) analytical column using
potassium dihydrogen phosphate buffer (adjusted to pH
3 by ortho phosphoric acid):methanol (70:30%, v/v) in
isocratic mode at a flow rate of 1 mL/min and column
at ambient temperature. All the solvents were filtered
through 0.45-m nylon filter and degassed in ultra-sonic
bath prior to use. Measurements were made with injec-
tion volume 20 L and detection at 225 nm. For analysis
of forced degradation samples, the PDA detector was
used in scan mode with a scan range of 200–400 nm.
The peak homogeneity was expressed in terms of peak
purity and was obtained spectral analysis report using
previously mentioned software. Final optimization was
performed with pure analytical standard which was
obtained from above mentioned pharmaceutical industry
(Table 1).
2.3.  Standard  solution  preparation
Accurately weigh and transfer 10 mg of amox and
10 mg of fluc working standard into a 10 mL clean dry
volumetric flask. Then, add about 7 mL of diluents and
sonicate to dissolve it completely and make volume up
to the mark with the same solvent (stock solution). Fur-Wavelength 225 nm
Injection volume 20 L
Column oven Ambient temperature
Run time 8 min
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Table 2
Assay of formulation.
Brand Drugs Mean peak area (n = 3)a Label claim (mg/cap) %Label claim
A Amoxicillin 5,278,539 250 100.2
Flucloxacillin 2,735,314 250 100.2
B Amoxicillin 5,301,612 250 100.2
Flucloxacillin 2,742,469 250 98.42
A
2
t
1
1
d
v
t
a
d
2
w, flucamox; B, flumox.
a Average mean of three determinations.
.4.  Analysis  of  formulations
20 capsules of two different brands were taken and
heir average weight was calculated. Dose equivalent to
0 mg of amox and fluc sample was transferred into a
00 mL clean dry volumetric flask, add about 70 mL of
iluent and sonicate to dissolve it completely and make
olume up to the mark with the same solvent (stock solu-
ion). Further pipette 6 mL of amox and fluc from the
bove stock solution into a 10 mL volumetric flask and
ilute up to the mark with diluents (Table 2 and Fig. 2).
.4.1. Calculations
AT
AS
× WS
DS
× DT
WT
× P
100
× avg. wt
LC
×  100
here
AS = average peak area counts of standard preparation;
AT = average peak area counts of sample preparation;
WS = weight of working standard taken in mg;
WT = weight of working test taken in mg;
P = percentage purity of working standard;
DT = dilution of test solution;
Fig. 1. Chromatogram of workingDS = dilution of standard solution;
LC = label claim of sample; avg. wt = average weight
of capsule in mg.
2.4.2.  Sample  details
The flucamox (Sedico Pharmaceuticals) and flumox
(Eipico) (each capsule 500 mg contains amox 250 and
fluc 250 mg).
2.5.  Preparation  of  calibration  curve
Calibration curve was established for fluc and amox
concentration ranging from 20 to 100 g/mL, respec-
tively.
2.6.  Forced  degradation  studies
The International Conference on Harmonization
(ICH) guideline entitled stability testing of new drug sub-
stances and products requires that stress testing is carried
out to elucidate the inherent stability characteristics of
the active substance [12]. The aim of this work was to
perform the stress degradation studies on the amoxicillin
and flucloxacillin using the proposed method.
 blank solution (placebo).
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togram Fig. 2. Chroma
2.7.  Standard  solution  preparation
Standard solution of 60 g/mL of fluc and amox was
prepared for forced degradation study and it was injected
into the HPLC system.
2.8.  Hydrolytic  degradation  under  acidic  condition
From 100 g/mL stock solution, 6 mL of stock solu-
tion and 1 mL of 0.1 N HCl were added in 10 mL
volumetric flask. Then, the volumetric flask was kept
at 60–70 ◦C reflux condition for 90 min and neutralized
with 0.1 N NaOH and 10 mL with diluent was made to
get concentration of 60 g/mL of fluc and amox. Cool
Fig. 3. Degradation chromatogrof formulation.
the solution to room temperature. Filter the solution with
0.45 m syringe filters and place in vials of the HPLC
system. No degradant peaks were reported in the reten-
tion time of fluc and amox (Fig. 3).
2.9.  Hydrolytic  degradation  under  alkaline
condition
From 100 g/mL stock solution, 6 mL of stock solu-
tion and 1 mL of 0.1 N NaOH were added in 10 mL
volumetric flask. Then, the volumetric flask was kept
at 60–70 ◦C reflux condition for 90 min and neutralized
with 0.1 N HCl and 10 mL with diluent was made to get
concentration of 60 g/mL of fluc and amox. Cool the
am of acidic condition.
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sFig. 4. Degradation chro
olution to room temperature. Filter the solution with
.45 m syringe filters and place in vials of the HPLC
ystem. No degradant peaks were reported in the reten-
ion time of fluc and amox (Fig. 4).
.10.  Oxidative  degradation
From 100 g/mL stock solution, 6 mL of stock solu-
ion and 1 mL of 3% (w/v) of hydrogen peroxide were
dded in 10 mL volumetric flask. Volumetric flask was
◦hen kept at 60–70 C reflux condition 90 min and vol-
me was made up to the mark with diluents to get
oncentration of 60 g/mL of fluc and amox. Cool the
olution to room temperature. Filter the solution with
Fig. 5. Degradation chromatogm of alkaline condition.
0.45 m syringe filters and place in vials of the HPLC
system. No degradant peaks were reported in the reten-
tion time of fluc and amox (Fig. 5).
2.11.  Thermal  induced  degradation
From 100 g/mL stock solution, 6 mL of stock
solution was added in 10 mL volumetric flask. Then, vol-
umetric flask was kept at 60–70 ◦C in hot air oven for
90 min and the volume was made up to the mark with
diluents to get concentration of 60 g/mL of fluc and
amox. Cool the solution to room temperature. Filter the
solution with 0.45 m syringe filters and place in vials
ram of peroxide study.
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romatoFig. 6. Degradation ch
of the HPLC system. No degradant peaks were reported
in the retention time of fluc and amox (Fig. 6).
2.12.  Photo  degradation
From 100 g/mL stock solution, 6 mL of stock solu-
tion was added in 10 mL volumetric flask. Above
samples were transferred into a petri dish and kept in
photostability chamber 200 W h/m2 in UV light and 1.2
million l  ×  h in visible light for 5 h. Then, the volumetric
flask was made up to mark with diluents to get concen-
tration of 60 g/mL of fluc and amox. Cool the solution
to room temperature. Filter the solution with 0.45 m
Fig. 7. Chromatogram ofgram of thermal study.
syringe. Filter and place in vials of the HPLC system.
No degradant peaks were reported in the retention time
of fluc and amox (Fig. 7).
3.  Validation  of  chromatographic  method
3.1.  Accuracy  or  recovery
Accuracy is represented and determined by recovery
experiments. In this method, recovery studies was per-
formed at three different percentage levels namely 80,
100 and 120 and finally analyzing amount recovered of
both drugs during studies.
 photolytic study.
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Table 3
Precision study.
Precisions Conc. (g/mL) Peak area (mean ± SD) (n = 6)a %RSD
amox fluc amox fluc amox fluc
System precision 60 60 5,251,606 ± 27,856.64 2,703,524 ± 23,038.92 0.53 0.85
Method precision 60 60 5,279,532.5 ± 8210.69 2,757,698 ± 22,377.85 0.15 0.81
Intermediate precision/ruggedness 60 60 5,278,539 ± 44,462.03 2,735,314 ± 16,323.24 0.84 0.59
a ndard d
3
s
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f
s
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w
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w
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t
t
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t
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c
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q
m
a
q
degradation products. To develop a stability-indicating
method different makes of C18, C8 column (Xterra,
Hypersil and Thermosil) and different mobile phases
Table 4
Summary of validation parameters.
Parameters Amoxicillin Flucloxacillin
Mean retention time (min) 2.575 3.407
Mean USP plate count 2601 2750.5
Mean USP resolution – 3mox, amoxicillin; fluc, flucloxacillin; % RSD, percentage relative sta
a Average mean of six determinations.
.2.  Speciﬁcity
To assess the method’s specificity, working blank
olution (placebo) without amox, fluc, standard solution
nd sample solution were injected into the system. It was
ound that chromatogram of working blank (placebo)
olution did not show any interference at the retention
ime of both amox and fluc. Specificity of the method
as also confirmed by forced degradation study. In peak
urity analysis with photo diode detector, purity angle
as less than purity threshold for both the analytes
Figs. 1 and 2).
.3.  Precision
Precision and intermediate precision/ruggedness of
he analytical method were established for both sys-
ems and method/procedure at 60 g/mL for both drugs.
ystem precision was determined by six replicate injec-
ions of standard solution injected into the HPLC system.
ethod precision was determined by the six individual
ample preparations injected to the HPLC system. The
elative standard deviation was found to be less than 2
Table 3).
.4.  Linearity
Linearity was demonstrated by preparing and ana-
yzing the standard preparation at five different
oncentrations for fluc and amox 20–100 g/mL. From
his experiment coefficient of correlation, intercept and
lope were calculated.
.5.  Limit  of  detection  (LOD)  and  limit  of
uantiﬁcation  (LOQ)The detection limit and quantitation limit were deter-
ined as signal to noise. The limit of detection for fluc
nd amox was 0.018 and 0.009 g/mL and the limit of
uantification was 0.06 and 0.03 g/mL, respectively.eviation.
3.6.  System  suitability  study
System suitability tests were carried out on freshly
prepared standard solution of flucloxacillin and amoxi-
cillin to check the various parameters such as plate count,
resolution and tailing factor (Table 4).
3.7.  Robustness  study
The robustness of the method was studied by small
changes in the method like altering the mobile phase
pH, flow rate, column temperature variation and changes
in mobile phase composition. It was observed that
there were not much changes in the chromatograms
(Table 5).
4.  Results  and  discussion
4.1.  Optimization  of  chromatographic  conditions
As there is a growing demand of flucloxacillin and
amoxicillin in pharmaceutical market, it is required to
develop fast, cost-effective, stable, precise and sensitive
analytical method LC for the simultaneous estimation
of both drugs. The primary target in developing this
stability-indicating RP-HPLC method is to achieve the
optimum resolution between the fluc and amox and itsMean tailing factor 1.35 1.4
Correlation of coefficient 0.9993 0.9992
Linearity range (g/mL) 20–100 20–100
Mean recovery (%) 99.7 99.9
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Table 5
Robustness study.
S. no. Parameter Modification USP plate count USP tailing factor
amox fluc amox fluc
1 Change in flow rate 0.8 mL/min 2254.9 2871 1.2 1.2
Optimized 2897. 2750.5 1.4 1.4
1.2 mL/min 2011.1 2138.4 1.2 1.1
2 Change in organic
composition of the
mobile phase
10% less 2316.1 2798.9 1.2 1.2
Optimizeda 2897 2750.5 1.4 1.4
10% more 2002.2 2141.1 1.2 1.2
3 Column temperature
variation
2 ◦C less 2033 2759 1.3 1.4
Optimizeda 2897 2750.5 1.4 1.4
2 ◦C more 2012 2742 1.4 1.4
4 Change in wavelength 5 nm less 2045 2762 1.3 1.4
Optimizeda 2897 2750.5 1.4 1.4
5 nm more 2015 2788 1.2 1.1
ambien
amox, amoxicillin; fluc, flucloxacillin.
a Optimized mobile phase composition and wavelength optimized (
containing buffers (pH 3–5):methanol in different ratios
were tried but failed to get optimum resolution between
drugs. This challenge was met by using dihydrogen
phosphate buffer (adjusted to pH 3 by ortho phos-
phoric acid):methanol (70:30, %v/v) where optimum
resolution and good symmetric peaks were observed by
using Thermosil C18 (4.6 mm ×  250 mm, 5 m) analyt-
ical column in isocratic mode at a flow rate of 1 mL/min
and column at ambient temperature. Under the above
optimized conditions, the retention time reported for for-
mulation was 2.582 min for amox and 3.407 min for fluc
(Fig. 2). The linearity of an analytical procedure was
demonstrated by preparing and analyzing the standard
preparation at five different concentrations of amox and
fluc (20–100 g/mL). The calibration curve constructed
for amoxicillin by plotting the peak area versus con-
centration yielded coefficient of regression R2 = 0.9993.
The mean recovery value for fluc and amox was 99.9
and 99.7, respectively. The limit of detection for fluc
and amox was 0.018 and 0.009 g/mL and the limit of
quantification was 0.06 and 0.03 g/mL, respectively.
The robustness study and percentage of assay of the for-
mulation were found within limit as per ICH Guidelines
[13]. The resolution was more than 3, theoretical plates
were more than 2500 and tailing factor was less than
1.5 for the flucloxacillin and amoxicillin peak. Speci-
ficity of the method was proved as the chromatogram
of working blank (placebo) solution does not show any
interference at the retention time of amox and fluc.
Therefore, the developed method was free from the
inference of diluents and excipients used in the formu-
lation.t) temperature.
4.2.  Forced  degradation  study
Degradation studies indicate the specificity of devel-
oped method in the presence of degradation products.
Degradation was carried out in combination of two
drugs and purity of drug peaks was confirmed by purity
angles. Formulation drug products were exposed to
thermal, hydrolytic under acid and base, oxidative, pho-
tolytic stress conditions. During degradation study, fluc
has been degraded slightly higher in acidic condition
when compared to alkaline condition and was found
to be more stable in thermal and photolytic condi-
tions but amox degraded more in thermal and photolytic
conditions. Although unknown degradant peaks were
observed in acid, base, peroxide, photolytic and ther-
mal study, no degradant peaks were reported in the
retention time of amox and fluc. Hence amox and fluc
stable up to specified period of time (90 min) in the
proposed method or they are susceptible towards acid,
alkali, heat, hydrogen peroxide and photolytic degrada-
tion (Table 6).
4.3.  Signiﬁcance  of  the  developed  method
Developed isocratic stability-indicating method has
many advantages over reported methods: (a) the method
was simple because mobile phase used was cheap and
easily available; (b) total run of chromatogram was 8 min
and both drugs were eluted within 3.5 min indicating that
very less amount of mobile phase was consumed; so the
method was cost-effective whereas in reported methods
it was more than 4.5 min; (c) the limit of detection for
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Table 6
Forced degradation study.
Parameters % of drug degraded Purity angle Purity threshold
amox fluc amox fluc amox fluc
Acid (heat at 60–70 ◦C for 90 min) 9.77 12.22 0.59 0.89 1.06 1.65
Base (heat at 60–70 ◦C for 90 min) 10.36 7.27 0.62 0.84 1.09 1.58
Peroxide (heat at 60–70 ◦C for 90 min) 8.5 7.1 0.43 0.92 1.13 1.67
Thermal (heat at 60–70 ◦C for 90 min) 13.54 5.84 0.52 0.74 1.18 1.69
Photolytic (kept in a photolytic camber for 5 h) 16.57 7.82 0.52 0.73 1.17 1.68
a
fl
0
0
m
(
i
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w
w
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i
a
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f
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fl
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v
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c
cmox, amoxicillin; fluc, flucloxacillin.
ucloxacillin and amoxicillin was 0.018 and
.009 g/mL and the limit of quantification was
.06 and 0.03 g/mL, respectively, indicating that the
ethod was sensitive and rapid; (d) specificity study
Figs. 1 and 2) and forced degradation study (Table 6)
ndicate that the method was very specific, stable in the
roposed method. Moreover, forced degradation study
as neither performed or nor reported elsewhere so it
as the first stability-indicating LC method for amox
nd fluc; (e) mode of separation is isocratic which means
t is easy to operate throughout the process without
ny complications whereas one of the reported method
as gradient elution techniques without stability study;
f) simultaneous estimation of different brands gives
recise results indicating that developed method is
ompatible to estimate in different pharmaceutical
ormulations; (g) validation of the developed method as
er ICH guideline indicates that the method was highly
recise, rapid, simple, economical, sensitive accurate,
obust and specific for simultaneous estimation of
uc and amox in bulk and pharmaceutical dosage
orm.
.  Conclusion
This method was proved to be simple, rapid, pre-
ise, selective and economical which can applied in
ifferent commercially available popular combinations
n pharmaceutical market used as antibiotic namely in
ummox, flucamox, suprapen without the interferences
f degradants product or excipients in bulk and phar-
aceutical dosage form. The developed method was
alidated as per ICH Guidelines and stability study in dif-
erent stress condition shows that the developed method
as highly specific and robust so that it can be effec-ively applied for routine analysis in research institutions,
n bio-analytical lab, in therapeutic drug monitoring for
linical trials, in quality control department of pharma-
eutical industries, in approved testing laboratories, in
[bio-equivalence studies and in clinical pharmacokinetic
studies.
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